scholarly journals The effects of selected biologics and a small molecule on Health-Related Quality of Life in adult plaque psoriasis patients: A systematic review and meta-analysis

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0241604
Author(s):  
Anna Karpińska-Mirecka ◽  
Joanna Bartosińska ◽  
Dorota Krasowska
Keyword(s):  
Quality Of Life ◽  
Plaque Psoriasis ◽  
Skin Diseases ◽  
Life Quality ◽  
Health Related Quality ◽  
True Effect Size ◽  
Study Results ◽  
Related Quality ◽  
Health Related

Background The Dermatology Life Quality Index (DLQI) is commonly used to assess the quality of life of patients with skin diseases. Clinical trials confirm the positive effect of the use of biologics and new molecules on the quality of life of patients with plaque psoriasis. Main objectives Investigation of the effect of infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib on Health-Related Quality of Life (HRQOL) measured by the DLQI in adult plaque psoriatic patients with respect to the patients’ race, type of used agent/placebo, agent’s dosage and treatment duration as well as the DLQI score prior to and after commencement of treatment. Material and methods Systematic literature searching for referential papers written in English using four databases: PubMed, EMBASE, Scopus, ClinicalTrials.gov as well as and manual searching (Google) Cochran’s (Q) and I2 tests were used for evaluation of heterogeneity or the degree of variation in the true effect size estimates between the analysed studies. The standardized mean difference (the SMD; Hedge’s g score) was applied to measure the differences between the two means (i.e. two groups: treated vs non-treated or treated vs placebo). The data coding and Hedge's g values were calculated according to the guidance of MetaXL software version 5.3. Main results 43 studies, in total 25,898 individuals, were evaluated by the DLQI and weighted mean scores were derived for the analysis. The mean DLQI scores ranged from 6.83 to 17.8 with the overall DLQI score of 12.12 (95%CI: 11.24 to 13.06). A random-effects model demonstrated significant considerable heterogeneity of the study results (I2 = 98%; p<0.001). Conclusion Infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib in adult plaque psoriatic patients improved HRQOL measured by the DLQI. The patients with lower quality of life before treatment obtained better results.

Health related quality of life of rosacea patients in China assessed by DLQI and willingness to pay: Cross-Sectional Questionnaire Study (Preprint)

2020 ◽  
Author(s):  
Yaqun Huang ◽  
Sha Yan ◽  
Hongfu Xie ◽  
Ben Wang ◽  
Zhixiang Zhao ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Willingness To Pay ◽  
Disease Duration ◽  
Life Quality ◽  
Cross Sectional Study ◽  
Health Related Quality ◽  
Cross Sectional ◽  
Related Quality ◽  
Health Related

BACKGROUND Rosacea is a chronic inflammatory dermatosis with facial skin involved, leading to physical and emotional problems, which greatly affected quality of life (QoL) of patients. Dermatology Life Quality Index (DLQI) and willingness to pay (WTP) are well-established instruments assessing the health-related quality of life (HRQoL), while very few studies have been focused on this topic about rosacea in China. OBJECTIVE To investigate HRQoL in Chinese rosacea patients assessed by DLQI and WTP and investigate potential predictors for patients with HRQoL severely affected. METHODS This cross-sectional study was conducted on 973 patients with rosacea. Sociodemographic data, clinical features and DLQI were collected, and WTP was assessed by three standardized items. Multivariable logistic analysis was performed to investigate independent factors influencing QoL. RESULTS 921 questionnaires were accomplished by participants. The mean DLQI score was 11.6 (median 11). Patients were willing to pay an average of $1050.2 or € 896.2 (median $431.4 or € 368.1) for complete cure. 33.3% would like to pay more than 20% of their monthly income to achieve sustainable control. There were positive correlations between WTP with DLQI (P < .05). DLQI could be independently impacted by age (21-30 and 31-40, OR = 3.242 and 3.617, respectively), the occupational requirement of appearance (high, OR = 4.410), disease duration (< 2 years, OR = 1.582), oedema (OR = 1.844) and severity of flushing, burning, stinging and pruritus (severe, OR = 2.003, 1.981, 2.491, 2.249, respectively). There were no significant associations between WTP and most of the clinical factors. CONCLUSIONS The QoL was negatively affected and should not be ignored among rosacea patients in China. Patients aged 21-40y, having occupational requirement of appearance, with the disease duration less than 2 years, and suffering severe flushing and related symptoms were more likely to have severe or very severe limitation of QoL.

scholarly journals Dermatology life quality index in psoriasis patients attending a tertiary care hospital: a study from North India

2020 ◽  
Vol 8 (9) ◽  
pp. 3277
Author(s):  
Faizan Younus Shah ◽  
Ifrah Shafat Kitab ◽  
Aaqib Aslam Shah ◽  
Faisal Younis Shah ◽  
Mohd Younus Shah ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Severe Disease ◽  
Life Quality ◽  
Health Related Quality ◽  
Disease Group ◽  
Moderate Disease ◽  
Related Quality ◽  
Health Related ◽  
The Impact

Background: Psoriasis affects nearly 1% of the world population. It can be a source of significant morbidity and psychological stress to the patient but is not lethal under ordinary circumstances. Patients suffering from the disease feel a lack of empathy on part of care-givers, family members, healthcare professionals as well as society in general. Dermatology life quality index (DLQI) is a questionnaire-based assessment of health related quality of life in patients suffering from skin disorders and has been seen to correlate well with the impact of the disease on a patient. This study was done to understand the impact of psoriasis on the overall well-being of patients using DLQI as the tool of assessment.Methods: The study included 40 cases of psoriasis that were assessed for the severity of the disease based on percentage body surface area involvement. The impact of disease severity and other factors on the quality of life of the patient was assessed using DLQI.Results: Out of 35 patients with BSA involvement <50% (mild and moderate disease), 28.6% (n=10/35) showed a very large or extremely large effect on the quality of life while no patient with a BSA involvement >50% (severe and very severe disease) reported the same. A small, moderate or no effect on the DLQI was seen in 71.4% (n=25/35) of cases from the mild and moderate disease group while 100% (n=5/5) of cases from severe and very severe disease group reported a similar effect. Thus, DLQI was not directly related to the extent of BSA involvement and was dependent on other factors as well.Conclusion: Age had a correlation with the effect of the disease on the quality of life of psoriasis cases. Patients who were younger were more likely to report stress and anxiety related to the recurrences seen with the disease. Patients with lesions on sites that are socially exposed like face, hands, scalp, etc. were more likely to feel embarrassed about their condition. Younger age, female gender, lesions on exposed sites and recently diagnosed patients (<12 months) were factors which had a significant impact on the health-related quality of life of patients. The severity of disease and extent of involvement were not always directly related to extent of impact on the quality of life.

Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis

Dermatology ◽  
2008 ◽  
Vol 216 (3) ◽  
pp. 260-270 ◽  
Author(s):  
Dennis A. Revicki ◽  
Mary K. Willian ◽  
Alan Menter ◽  
Jean-Hilaire Saurat ◽  
Neesha Harnam ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Response ◽  
Plaque Psoriasis ◽  
Response To Therapy ◽  
Health Related Quality ◽  
Life Outcomes ◽  
Severe Plaque Psoriasis ◽  
Related Quality ◽  
Health Related

scholarly journals Health-Related Quality of Life Impairment among Patients with Different Skin Diseases in Vietnam: A Cross-Sectional Study

2019 ◽  
Vol 16 (3) ◽  
pp. 305 ◽  
Author(s):  
Sau Huu Nguyen ◽  
Long Hoang Nguyen ◽  
Giang Thu Vu ◽  
Cuong Tat Nguyen ◽  
Thu Hoai Thi Le ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Skin Diseases ◽  
Cross Sectional Study ◽  
Health Related Quality ◽  
Sectional Study ◽  
Cross Sectional ◽  
Related Quality ◽  
Health Related ◽  
Anxiety Depression

Skin diseases have caused a heavy burden on the infected population worldwide. This study aimed to examine the health-related quality of life (HRQOL) among patients with different skin diseases and identify associated factors. A cross-sectional study with 430 participants was conducted at the Vietnam National Hospital of Dermatology and Venereology (NHD) from September to November 2018. The EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) instrument was employed, which measures the EQ-5D index from five domains including mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Multivariate Tobit regression was adopted to determine factors that were associated with HRQOL (EQ-5D index). The rate of atopic dermatitis was the highest with 28.8%, following by contact dermatitis (17.0%) and skin fungal infections (13.0%). Regarding HRQOL, anxiety/depression was the most common health problem in patients with skin diseases (71.8%), following by pain/discomfort (63.6%). The mean EQ-5D index score was 0.73 (SD = 0.19). The lowest EQ-5D index scores were obtained for females with skin infections (mean = 0.52) and for males with psoriasis (mean = 0.59). Females had significantly lower scores compared to males (Coef. = −0.06; 95% CI = −0.11 to −0.01). Higher income and living in rural areas were also negatively correlated with the EQ-5D index. This study demonstrated the low HRQOL among patients with skin diseases in Vietnam and emphasized the vulnerability of patients with different socioeconomic statuses to their HRQOL.

Health-related quality of life measures in routine clinical care: Can FACT-Fatigue help to assess the management of fatigue in cancer patients?

2009 ◽  
Vol 25 (01) ◽  
pp. 90-96 ◽  
Author(s):  
Maria-Jose Santana ◽  
Heather-Jane Au ◽  
Melina Dharma-Wardene ◽  
Joanne D. Hewitt ◽  
David Dupere ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Clinical Care ◽  
Health Related Quality ◽  
Routine Clinical Care ◽  
Study Results ◽  
Related Quality ◽  
Health Related

Objectives:Fatigue is the most common symptom reported by cancer patients. The inclusion of health-related quality of life (HRQL) measures in routine clinical care of cancer patients may improve the management of fatigue. The primary objective of this study is to provide evidence on the magnitude of change in fatigue subscale scores using the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) that is clinically important.Methods:Consecutive patients with advanced primary lung cancer attending a Canadian tertiary care cancer and, prior to undergoing palliative chemotherapy, were enrolled in the study. Patients completed a battery of questionnaires [FACT-F, Qualitative Patients Self-report of Fatigue Level (QPSRF)] at baseline, follow-up and 2 weeks after their final cycle of chemotherapy. Clinicians assessed the patients using the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale at baseline and each follow-up visit. FACT-F change scores were computed as the mean change in score (end of study score minus baseline score).Results:A total of 43 patients with mean age of 59 years were enrolled in the study. Results revealed a mean change in FACT-F subscale score of 5.0 (SE 1.06) for those who rated themselves as more tired, 1.28 (SE 1.00) for those who rated themselves as the same (no change), and −1.52 (SE 0.84) for those patients who rated themselves as less tired.Conclusions:We provide evidence on the magnitude of change in FACT-F score that is associated with the perception by patients of improvement in fatigue and magnitude of change in score that is associated with worsening in fatigue.

scholarly journals Research on Influence of Clopidogrel on Life Quality in Patients with Transient Ischemic Attack and its Influencing Factors

2018 ◽  
Vol 1 (1) ◽  
pp. 16
Author(s):  
Lanbo Chen ◽  
Xiaohong Gu ◽  
Bo Dong
Keyword(s):  
Quality Of Life ◽  
Influencing Factors ◽  
Transient Ischemic Attack ◽  
Life Quality ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Ischemic Attack ◽  
Aspirin Group

Purpose: To analyze the basic situation and health related quality of life (HRQOL) results of patients with transient ischemic attack (TIA), and to study the influencing factors of health related quality of life in patients receiving clopidogrel. Method: Divide the TIA patients into clopidogrel group, aspirin group and untreated group. Measure HRQOL scores of TIA patients using the short form 36 questionnaire (SF-36) scale and analyze influencing factors of HRQOL with one-way ANOVA and multivariate stepwise linear regression statistical methods. Results: The differences of HRQOL scores among three groups are of statistical significance (F = 4.29, P = 0.00). There is no difference in HRQOL score between clopidogrel group and aspirin group (t = 5.35, P = 0.00), but HRQOL scores of clopidogrel group and aspirin group are higher than those of the untreated group (t = 6.14, P = 0.00; t = 5.16, P = 0.00). The HRQOL scores of clopidogrel group are positively correlated with diet, exercise, gender and family harmony (P < 0.05), but negatively correlated with diabetes, hypertension, smoking, drinking, hyperlipidemia, age, career and ABCD2 score (P < 0.05). Conclusion: TIA patients who received secondary prevention with clopidogrel and aspirin show better life quality results than those who did not. There were many factors influencing clopidogrel's treatment effect. Paying attention to middle-aged and elderly, the obese, mental workers and female TIA patients, teach TIA patients to quit smoking, drinking and eating low-salt and low-fat food, actively treating their hypertension, hyperlipidemia and diabetes and laying emphasis on psychological counseling and exercise can significantly improve the treatment effect of clopidogrel. 

Sign in / Sign up

Export Citation Format

Share Document